Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · IEX Real-Time Price · USD
2.240
-0.250 (-10.04%)
At close: Mar 28, 2024, 4:00 PM
2.470
+0.230 (10.27%)
After-hours: Mar 28, 2024, 5:28 PM EDT
Company Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc.
Country | United States |
Founded | 2000 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 7 |
CEO | Jeffrey A. Meckler |
Contact Details
Address: 3 Columbus Circle, 15th Floor New York, New York 10019 United States | |
Phone | (646) 427-2727 |
Website | indaptusrx.com |
Stock Details
Ticker Symbol | INDP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001857044 |
CUSIP Number | 45339J105 |
ISIN Number | US45339J1051 |
Employer ID | 86-3158720 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Jeffrey A. Meckler | Chief Executive Officer and Director |
Walt Addison Linscott Esq. | Chief Operating Officer |
Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer and Director |
Nir Sassi | Chief Financial Officer, Secretary and Treasurer |
Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 25, 2024 | 8-K | Current Report |
Mar 13, 2024 | 424B5 | Filing |
Mar 13, 2024 | 10-K | Annual Report |
Mar 13, 2024 | 8-K | Current Report |
Mar 4, 2024 | 8-K | Current Report |
Jan 23, 2024 | 8-K | Current Report |
Nov 6, 2023 | 10-Q | Quarterly Report |
Nov 6, 2023 | 8-K | Current Report |
Nov 6, 2023 | 8-K | Current Report |
Oct 31, 2023 | 8-K | Current Report |